Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

2007

 
14.12.2007
Antitope Limited, UK. Announces EpiScreen™ Collaboration with UCB Celltech
12th December 2007 -Antitope Ltd. today announced a research collaboration with UCB Celltech ("UCB") where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic monoclonal antibodies. "We are very pleased to be working with UCB whom we recognize as a...
19.11.2007
Antitope Ltd Announces EpiScreen™ Collaboration With Centocor Inc
19 November 2007, Cambridge (UK) - Antitope Ltd., today announced they have entered into a research collaboration with Centocor Inc.. The research collaboration will employ Antitope's EpiScreenTM technology to assist Centocor in evaluating the immunogenicity of protein therapeutic leads for...
25.09.2007
Antitope Announces Research Agreement with Fraunhofer Institute for Cell Therapy and Immunology
18th September 2007 - Antitope Ltd., a leader in antibody and protein engineering, today announced a research agreement with Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI). Under the Agreement, Antitope will engineer a novel antibody developed by Fraunhofer IZI to produce an...
01.08.2007
Antitope and ProtAb Ltd. (Israel) - an HBL Portfolio Company, Announce Antibody Research Agreement
July 30th, 2007 - Cambridge / Jerusalem - Antitope Ltd., inventors of the Composite Human AntibodyTM technology, announced a research and product development agreement with ProtAb Ltd. (a wholly-owned portfolio company of Hadasit Bio-Holdings Ltd, traded on the Tel Aviv Stock Exchange: HDST) for...
24.04.2007
Antitope Announces Composite Protein Research Agreement with Cambridge Antibody Technology
24th April 2007 Antitope Ltd., announced a research agreement with the Cambridge Antibody Technology (CAT) for the generation of novel biologics for the potential treatment of cancer. As part of the agreement, Antitope will apply its proprietary Composite ProteinTM and EpiScreenTM technologies...
23.04.2007
Antitope Announces a Research Agreement with Medtronic, Inc. to Develop a Composite Human Antibody
23th April 2007 - Antitope Ltd. today announced a research agreement with Medtronic Inc. for the generation of a novel biologic. As part of the agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology to produce a therapeutic antibody with a reduced risk of...
27.03.2007
Antitope Present at "Recombinant Antibodies", Berlin, Germany, June 26th 2007
Dr Frank Carr, Director of Biologics Research will be presenting a paper entitled "Therapeutic Antibodies Without Helper T cell Epitopes". This paper will discuss the process and benefits of engineering antibodies without T cell epitopes to minimize the risk of immunogenicity in the...
23.02.2007
Antitope Limited, UK. Announces Antibody Research Agreement with Dana-Farber Cancer Institute, Inc.
23rd February 2007 - Antitope Ltd., announced a research agreement with the Dana Farber Cancer Institute, Inc. ("Dana-Farber") for the generation of novel biologics for the potential treatment of cancer and infectious disease. As part of the agreement, Antitope will apply its proprietary...
10.01.2007
Antitope Limited, UK. Announces Antibody Research Agreement with ARIUS Research, Inc
Antitope Limited, UK. Announces Antibody Research Agreement with ARIUS Research, Inc. - 10th January 2007. Antitope Ltd., a leader in the development of Composite Human Antibody technology for the generation of therapeutic antibodies, announced a research agreement with ARIUS Research, Inc....